Article
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Cancer chemotherapy and pharmacology - 1 May 2011
Aogi Kenjiro, Yoshida Masayuki, Sagara Yoshiaki, Kamigaki Shunji, Okazaki Minoru, Funai Jumpei, Fujimoto Toshio, Toi Masakazu, Saeki Toshiaki, Takashima Shigemitsu
Abstract excerpt
PURPOSE: Gemcitabine (GEM)-paclitaxel combination therapy has been confirmed as a standard therapy for metastatic/recurrent breast cancer (MBC) in Western countries. This study was conducted to assess the efficacy and safety of GEM-paclitaxel combination therapy in Japanese MBC patients. METHODS: Patients were administered paclitaxel 175 mg/m(2) on day 1, and GEM 1,000 or 1,250 mg/m(2) on days 1 and 8 of 21-day...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.